Browse our 650+ Publications​

Latest Publications

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma

Konduri V, et al.
Science Translational Medicine
May 2021
Authors and Affiliates
Vanaja Konduri 1, Sujith K Joseph 2,3, Tiara T Byrd 2,3, Zeid Nawas 2,3, Jonathan Vazquez-Perez 1, Colby J Hofferek 1, Matthew M Halpert 1, Dongliang Liu 4, Zhengdong Liang 4, Yunyu Baig 1, Vita S Salsman 2,3, Damilola Oyewole-Said 1, Anna Tsimelzon 5, Briana A Burns 1, Changyi Chen , 6, Jonathan M Levitt 1,5,7, Qizhi Yao 1,4,8,9, Nabil M Ahmed 2,3,8, Meenakshi Hegde 2,3,8, William K Decker 10,2,8; 1 Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA. 2 Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA. 3 Department of Pediatrics, Division of Hematology and Oncology, Baylor College of Medicine, Houston, TX 77030, USA. 4 Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. 5 Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA. 6 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA. 7 Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA. 8 Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. 9 Michael E. DeBakey VA Medical Center, Center for Translational Research on Inflammatory Diseases (CTRID), Houston, TX 77030, USA. 10 Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA. decker@bcm.edu.

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Platten M, et al.
Nature
May 2021
Authors and Affiliates
Michael Platten 1,2,3, Lukas Bunse 4,5, Antje Wick 6,7, Theresa Bunse 4,5, Lucian Le Cornet 8, Inga Harting 9, Felix Sahm 10,11, Khwab Sanghvi 4, Chin Leng Tan 4, Isabel Poschke 4,12, Edward Green 4, Sune Justesen 13, Geoffrey A Behrens 14, Michael O Breckwoldt 9, Angelika Freitag 8, Lisa-Marie Rother 8, Anita Schmitt 15, Oliver Schnell 16, Jörg Hense 17, Martin Misch 18, Dietmar Krex 19, Stefan Stevanovic 20, Ghazaleh Tabatabai 21, Joachim P Steinbach 22, Martin Bendszus 9, Andreas von Deimling 10,11, Michael Schmitt 15, Wolfgang Wick 6,7,23; 1 DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.platten@dkfz.de. 2 Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany. m.platten@dkfz.de. 3 Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany. m.platten@dkfz.de. 4 DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 5 Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany. 6 Neurology Clinic, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany. 7 NCT, Heidelberg, Germany. 8 NCT Trial Center, NCT, Heidelberg, Germany. 9 Department of Neuroradiology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany. 10 DKTK CCU Neuropathology, DKFZ, Heidelberg, Germany. 11 Department of Neuropathology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany. 12 Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany. 13 Immunitrack, Copenhagen, Denmark. 14 DKMS Life Science Lab GmbH, Dresden, Germany. 15 Department of Internal Medicine V, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany. 16 Department of Neurosurgery, University of Freiburg, Freiburg, Germany. 17 Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. 18 Department of Neurosurgery, Charité Medical Center, University of Berlin, Berlin, Germany. 19 Department of Neurosurgery, Carl Gustav Carus University Hospital, University of Dresden, Dresden, Germany. 20 Institute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. 21 Department of Neurology, University of Tübingen, Tübingen, Germany. 22 Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany. 23 DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany.

Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses

Dykema AG, et al.
Journal of Clinical Investigation
May 2021
Authors and Affiliates
Arbor G Dykema 1, Boyang Zhang 2, Bezawit A Woldemeskel 3, Caroline C Garliss 3, Laurene S Cheung 4, Dilshad Choudhury 1, Jiajia Zhang 1, Luis Aparicio 1, Sadhana Bom 1, Rufiaat Rashid 1, Justina X Caushi 1, Emily Han-Chung Hsiue 1, Katherine Cascino 3, Elizabeth A Thompson 5, Abena K Kwaa 3, Dipika Singh 1, Sampriti Thapa 1, Alvaro A Ordonez 6, Andrew Pekosz 7, Franco R D'Alessio 3, Jonathan D Powell 1, Srinivasan Yegnasubramanian 1, Shibin Zhou 5, Drew M Pardoll 1, Hongkai Ji 2, Andrea L Cox 5, Joel N Blankson 3, Kellie N Smith 4; 1 Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, United States of America. 2 Department of Biostatistics, Johns Hopkins University School of Medicine, Baltimore, United States of America. 3 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, United States of America. 4 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, United States of America. 5 Johns Hopkins University School of Medicine, Baltimore, United States of America. 6 Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, United States of America. 7 Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Medicine, Baltimore, United States of America.

IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy

Kohli K, et al.
Journal for ImmunoTherapy of Cancer
May 2021
Authors and Affiliates
Karan Kohli 1,2,3, Lu Yao 4, Theodore Scott Nowicki 5, Shihong Zhang 1, Ralph Graeme Black 1, Brett A Schroeder 1,2,6, Erik A Farrar 7, Jianhong Cao 1, Heather Sloan 1, Dawn Stief 1, Lee D Cranmer 1,2, Michael J Wagner 1,2, Douglas S Hawkins 8, Venu G Pillarisetty 3, Antoni Ribas 9, Jean Campbell 1,10, Robert H Pierce 1,10, Edward Y Kim 11, Robin L Jones 12, Stanley R Riddell 1,3,13, Cassian Yee 7, Seth M Pollack 14,3,15; 1 Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA. 2 Division of Oncology, University of Washington, Seattle, WA, USA. 3 Department of Surgery, University of Washington, Seattle, WA, USA. 4 Poseida Therapeutics, San Diego, CA, USA. 5 Division of Pediatric Hematology/Oncology, University of California, Los Angeles, California, USA. 6 Department of Internal Medicine, Virginia Mason Medical Center, Seattle, WA, USA. 7 MD Anderson, Houston, TX, USA. 8 Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA, USA. 9 Division Hematology and Oncology, University of California, Los Angeles, UK. 10 Sensei Biotherapeutics, Gaithersburg, Boston, MD, USA. 11 Department of Radiation Oncology, University of Washington, Seattle, WA, USA. 12 Sarcoma, Royal Marsden Hospital and Institute of Cancer Research, London, UK. 13 Lyell Immunopharma, Seattle, WA, USA. 14 Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA Seth.pollack@northwestern.edu. 15 Division of Oncology, Northwestern University, Chicago, IL, USA.

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

Abbas HA, et al.
Frontiers in Immunology
May 2021
Authors and Affiliates
Hussein A Abbas 1, Patrick K Reville 1, Xianli Jiang 2, Hui Yang 3, Alexandre Reuben 4, Jin Seon Im 5,6, Latasha Little 7, Jefferson C Sinson 7, Ken Chen 2, Andrew Futreal 6,7, Guillermo Garcia-Manero 3; 1 Division of Cancer Medicine, Medical Oncology Fellowship, University of Texas MD Anderson Cancer Center, Houston, TX, United States. 2 Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States. 3 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States. 4 Department of Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States. 5 Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, United States. 6 Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 7 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Associations between T cell infiltration, T cell receptor clonality, histology and recurrence in renal cell carcinoma

Gadot M, et al.
Clinical and Experimental Immunology
May 2021
Authors and Affiliates
Moran Gadot 1, Mordechay Gal 2, Paula Dobosz 3, Zohar Dotan 4 5, Jacob Ramon 4,5, Raanan Berger 1,5, Dror Avni 6, Eduard Fridman 7, Raya Leibowitz 5,8; 1 Oncology institute, Tel-Hashomer, Sheba medical center, Israel. 2 Faculty of life science, Bar Ilan University, Ramat-Gan, Israel. 3 Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland. 4 Department of Urology, Tel-Hashomer, Sheba medical center, Israel. 5 Faculty of medicine, Tel-Aviv university, Tel-Aviv, Israel. 6 Laboratory of molecular cell biology, Tel-Hashomer, Sheba medical center, Israel. 7 Pathology institute, Tel-Hashomer, Sheba medical center, Israel. 8 Oncology institute, Shamir medical center, Zerifin, Israel.

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Advani R, et al.
Blood
April 2021
Authors and Affiliates
Ranjana Advani 1, Alison J Moskowitz 2, Nancy L Bartlett 3, Julie Vose 4, Radhakrishnan Ramchandren 5, Tatyana Feldman 6, Ann S LaCasce 7, Beth Christian 8, Stephen M Ansell 9, Craig H Moskowitz 10, Lisa Brown 11, Chiyu Zhang 12, David Taft 13, Sahar Ansari 12, Mariana Sacchi 14, Linda Ho 12, Alex F Herrera 15; 1 Stanford University, Stanford, California, United States. 2 Memorial Sloan Kettering Cancer Center, New York, New York, United States. 3 Washington University School of Medicine, St. Louis, Missouri, United States. 4 University of Nebraska Medical Center, Omaha, Nebraska, United States. 5 The University of Tennessee Graduate School of Medicine, Knoxville, Tennessee, United States. 6 Hackensack University Medical Center, Hackensack, New Jersey, United States. 7 DFCI, Boston, Massachusetts, United States. 8 The Ohio State University, Columbus, Ohio, United States. 9 Mayo Clinic, Rochester, Minnesota, United States. 10 University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States. 11 Zymeworks Pharmaceuticals, United States. 12 Seagen Inc., Bothell, Washington, United States. 13 Seattle Genetics Inc, Bothell, Washington, United States. 14 Bristol-Meyers Squibb, Princeton, New Jersey, United States. 15 City of Hope National Medical Center, Duarte, California, United States.

Distinct biomarker profiles and TCR sequence diversity characterize the response to PD-L1 blockade in a mouse melanoma model

Meskini RE, et al.
Molecular Cancer Research
April 2021
Authors and Affiliates
Rajaa El Meskini 1, Devon Atkinson 1, Alan Kulaga 2, Abdalla Abdelmaksoud 3, Michelle Gumprecht 1, Nathan Pate 1, Susana Hayes 4, Michael Oberst 4, Ian M Kaplan 5, Patrick Raber 6, Terry Van Dyke 7, Shyam K Sharan 8, Robert Hollingsworth 9, Chi-Ping Day 10, Glenn Merlino 11, Zoe Weaver Ohler 12; 1 Center for Advanced Preclinical Research, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research (FNLCR). 2 Center for Advanced Preclinical Research, SAIC at Frederick National Laboratory for Cancer Research. 3 CCR Collaborative Bioinformatics Resource, National Cancer Institute. 4 AstraZeneca (United States). 5 Adaptive Biotechnologies (United States). 6 Research, Adaptive Biotechnologies (United States). 7 Mouse Cancer Genetics Program, Center for Advanced Preclinical Research, National Cancer Institute. 8 Mouse Cancer Genetics Program, National Cancer Institute. 9 Oncology Research and Development, Pfizer (United States). 10 National Cancer Institute, National Institutes of Health. 11 Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute. 12 Center for Advanced Preclinical Research, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research zweaverohler@mail.nih.gov.

Select antitumor cytotoxic CD8 + T clonotypes expand in patients with chronic lymphocytic leukemia treated with ibrutinib

Baptista MJ, et al.
Clinical Cancer Research
April 2021
Authors and Affiliates
Maria Joao Baptista 1, Sivasubramanian Baskar 2, Erika M Gaglione 3, Keyvan Keyvanfar 4, Inhye Ahn 5, Adrian Wiestner 6, Clare Sun 7; 1 Hematology Branch, National Heart Lung and Blood Institute. 2 Hematology Branch, Lymphoid Malignancies Section, National Heart, Lung and Blood Institute, National Institutes of Health. 3 Hematology Branch, NHLBI,NIH. 4 Hematology Branch, NHLBI/NIH. 5 National Heart, Lung and Blood Institute, National Institutes of Health. 6 Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health. 7 Hematology Branch, National Heart Lung and Blood Institute clare.sun@nih.gov.
Previous Next